AQP1 and cardiac hypertrophy: The clinically approved AQP1 inhibitor, Bacopaside II, a triterpene saponin natural compound, impaired AQP1-mediated H2O2 permeability in mice and human myocytes, attenuating cardiac hypertrophy in a murine model [134].